Faricimab: current evidence for the treatment of retinal vein occlusion.
Graefes Arch Clin Exp OphthalmolJun 10, 2026 (epub)
Livio Vitiello, Giuseppe Giannaccare, Enrico Borrelli et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluates the efficacy and safety of faricimab for treating macular edema due to retinal vein occlusion (RVO). It synthesizes data from pivotal phase III trials and real-world studies, finding that faricimab achieves visual and anatomical outcomes comparable to aflibercept, with efficacy maintained for up to 72 weeks. However, its superiority in treatment durability remains unproven.
Key findings
- Faricimab achieved visual and anatomical outcomes comparable to aflibercept 2.0 mg during fixed monthly dosing.
- Efficacy was maintained for up to 72 weeks under treat-and-extend regimens.
- A clinically meaningful proportion of patients achieved extended treatment intervals, potentially reducing treatment burden.
- Functional improvement was more heterogeneous, especially in chronic or therapy-resistant cases.
Why it matters
Understanding the effectiveness and safety of faricimab in RVO can help clinicians make informed decisions about treatment options, particularly in managing patient care and optimizing treatment regimens.